Strengthening regulatory capacity for gene drives in Africa: leveraging NEPAD’s experience in establishing regulatory systems for medicines and GM crops in Africa
Tóm tắt
The New Partnership for Africa’s Development (NEPAD) Agency recognizes that Africa is in a period of transition and that this demands exploring and harnessing safe advances made in science-based innovations including modern biotechnology. To advance the science of biotechnology in Africa effectively, while at the same time safeguarding human health and the environment, the African Union (AU) adopted a High-Level Panel report on modern biotechnology entitled, Freedom to Innovate, which advocated for a coevolutionary approach where technology development goes hand in hand with regulation. Furthermore, most AU member states are Parties to the Cartagena Protocol on Biosafety (CPB), a legally binding international agreement negotiated, concluded and adopted within the framework of the Convention on Biological Diversity. This seeks to guide Parties in developing systems for the environmentally sound management of modern biotechnology applications. Currently, 49 AU Member States have signed and ratified the CPB, of which 12 have passed biosafety laws. African Union (AU) member states are at different stages in the development of regulatory frameworks for applications of modern biotechnology, which include genetically modified (GM) products and other emerging technologies. Biosafety regulatory frameworks comprise: biotechnology and/or biosafety policy; laws, regulations and guidelines; administrative systems; decision-making systems; and mechanisms for public engagement. To assist Member States to implement functional regulatory frameworks for both agriculture and health applications, the NEPAD Agency established the African Biosafety Network of Expertise (ABNE) and the African Medicines Regulatory Harmonization (AMRH). Currently, transgenic insects and GM crops are regulated by Competent National Authorities whose mandate derives from national biosafety laws. For GM crops, a lot of research has been conducted up to the confined field trial (CFT) and multi-location trials stages in a number of African countries. Burkina Faso has fully functional containment facilities for transgenic mosquitoes while Mali and Uganda are developing theirs. The Burkina Faso regulatory agency has granted permits and has already received sets of sterile mosquito eggs for trials in the contained facility. It is instructive to note that both ABNE and AMRH have worked with national and regional regulatory bodies in Africa to enhance their technical capacities for informed decision making, adoption of best practices, and compliance with international standards. It is against the backdrop of a rich blend of on-the-ground knowledge, experience, expertise, and insight into the context and political sensitivities of member states that the NEPAD Agency seeks to expand existing support. This would include capacity strengthening in the regulation of emerging technologies, such as the application of gene drives in the development of transgenic mosquito for the control of malaria transmission.
Tài liệu tham khảo
Sachs J. A new map of the world. De Economist 2000; http://www.economist.com/node/80730. Accessed 3 Oct 2016.
UNESCO: UNESCO Science Report. 2010; 299. https://www.scribd.com/document/42199956/Unesco-Science-Report-2010. Accessed 3 Oct 2016.
NEPAD Planning and Coordinating Agency (NPCA): AU–NEPAD (African union–new Partnership for Africa’s development) - all Africa innovation outlook. 2010;107 http://allafrica.com/download/resource/main/main/idatcs. Accessed 3 Oct 2016.
Malabo Declaration, 2014 http://www.fao.org/food-loss-reduction/news/detail/en/c/250883/ Accessed 3 Nov 2017.
Gardner CA, Acharya T, Yack D. Technological And Social Innovation: A Unifying New Paradigm For Global Health 2007; http://content.healthaffairs.org/content/26/4/1052.full. Accessed 3 Oct 2016.
ISAAA: GM approval database. 2016; http://www.isaaa.org/gmapprovaldatabase/default.asp. Accessed 20 Oct 2016.
Ricroch AE, Hénard-Damave MC. Next biotech plants: new traits, crops, developers and Technologies for Addressing Global Challenges. Crit Rev Biotechnol. 2015:1–16. https://doi.org/10.3109/07388551.2015.1004521
Horvath P, Barrangou R. CRISPR/Cas, the immune system of Bacteria and archaea. Science. 2010;67, 327 https://doi.org/10.1126/science.1179555.
Zetsche B, Gootenberg JS, abudayyeh OO, Slaymaker IM, Makarova KS, Essietzbichler P, Votz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;(3):759–71.
Fonfara I, Richter H, Bratovič M, Le Rhun A, Charpentier E. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature. 2016;532(7600):517–21. https://doi.org/10.1038/nature17945. PMID 27096362
Lusser MC, Parisi C, Plan D, Cerezo R. New Plant Breed techniques. State of the Art and prospects from commercial Development EUR-Scientific Research Series. Luxembourg: Publications office of the European Union; 2011. https://doi.org/10.2791/54761.
Joung JK, Sander J. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013;14:49–55. https://doi.org/10.1038/nrm3486.
Caroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188:733–82. http://www.ncbi.nlm.nih.gov/pmc/artciles/PMC3445556/-PONE.0045035-Caroll1
Pavletich NP, Pabo C. Zinc finger DNA recognition: crystal stracuture of Zif268-DNA complex at 2.1 a. Science. 1991;252(5007):809–17.
Werren JH. Biology of wolbachia. Annu Rev Entomol. 1997;42:587–609. https://doi.org/10.1146/annurev.ento.%2042.1.587.
Burt A, Trivers R. Genes in conflict: the biology of selfish genetic elements. Cambridge: Harvard University Press; 2006.
Alphey L. Genetic control of mosquitoes. Annu Rev Entomol. 2014;59:205–24. https://doi.org/10.1146/annurev-ento-011613-162002.
Esvelt KM, Smidler AL, Catteruccia F, Church GM. Emerging technology: concerning RNA-guided gene drives for the alteration of wild populations. eLife. 2014;10 https://doi.org/10.7554/eLife.03401.
Hammond A, Galizi R, Kyrou K, Simoni A, Siniscalchi C, Katsanos D, Gribble M, Baker D, Marois E, Russell S, Burt A, Windbichler N, Crisanti A, Nolan T. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol. 2016;34(1):78–83. https://doi.org/10.1038/nbt.3439.
Prudhomme O'Meara W, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010:545–55.
Africa Biosafety Network of Expertise (ABNE). 2016; http://nepad-abne.net/about-us/who-we-are/ (Accessed 3 Nov 2017.
Juma C, Serageldin I. Freedom to innovate: biotechnology in Africa's development. Pretoria, South Africa: report for new Partnership for Africa's. Development. 2007; http://belfercenter.ksg.harvard.edu/publication/17382/freedom_to_innovate.html. Accessed 10 Aug 2016
New Partnership for Africa's Development (NEPAD). The African Medicine Regulatory Harmonization Programme Annual Report, vol. 2016.
African Union: Model law on medical products regulation. 2016; http://www.nepad.org/resource/african-union-au-model-law-medical-products-regulation. Accessed 10 Oct 2016; convention on biological diversity (CBD). 2016; http://www.cbd.int/convention/text/
New Partnership for Africa's Development (NEPAD): Guide for Regional Centres of Regulatory Excellence. 2014.
New Partnership for Africa's Development (NEPAD) 2016; http://www.nepad.org/content/about-nepad#aboutourwork. Accessed 10 Aug 2016.
National Academies of Sciences, Engineering, and Medicine. Gene drives on the horizon: advancing science, navigating uncertainty, and aligning research with public values. Washington: National Academies Press; 2016. https://doi.org/10.17226/23405.